210, 1167 Kensington Cr. N.W
Canada T2N 1X7
FOR IMMEDIATE RELEASE
Oncolytics Biotech ® Inc. Announces Issuance of 35 th U.S. Patent
CALGARY, AB --- June 17, 2010 - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) (“Oncolytics”)
today announced that it has been granted its 35 th U.S. Patent, No. 7,731,951 entitled “Viruses for the Treatment
of Cellular Proliferative Disorders.” The patent claims cover methods for treating cell proliferative disorders by
administering modified vaccinia virus to proliferating cells having an activated Ras-pathway.
“This patent provides further coverage with respect to the use of a range of modified viruses to treat a variety of
different cancers,” said Mary Ann Dillahunty, Vice President of Intellectual Property for Oncolytics.
Oncolytics now has issued patents that cover methods for treating proliferative disorders using modified
adenovirus, HSV, parapoxvirus and vaccinia virus in addition to an extensive patent portfolio covering oncolytic
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as
potential cancer therapeutics. Oncolytics’ clinical program includes a variety of human trials including a Phase III
trial in head and neck cancers using REOLYSIN ® , its proprietary formulation of the human reovirus. For further
information about Oncolytics, please visit: www.oncolyticsbiotech.com .
This news release contains forward-looking statements, within the meaning of Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking statements, including among others, the
Company’s belief as to the importance of the issuance of this patent, the safety and efficacy of the
reovirus, the Company’s expectations as to the potential applications of the patented technology and
other statements relating to anticipated developments in the Company’s business and technologies,
involve known and unknown risks and uncertainties t